January 13, 2020 – myBrain Technologies announces its presence at the Encephalus 2020 Congress from January 22 to 24 at the Palais des Congrès in Paris

Meet the myBrain Technologies team at booth 33.

All information about the program can be found here.

L’article Brain Congress – myBrain Technologies presents from January 22 to 24, 2020 est apparu en premier sur Melomind.

Reinforcement of the digital marketing strategy for the deployment
of melomind TM to the general public

Involvement in the medical sector for the treatment of
anxiety disorders and depression by neurofeedback

Appointment of Philippe Hartmanshenn, Chief Operating Officer (COO)

 

Paris, France – May 13, 2020 – myBrain Technologies, a company specializing in neurotechnology solutions to improve the management and treatment of stress, anxiety and depression through neurofeedback, announces its new ambitions.

After designing and developing melomind TM, a neurofeedback device that allows each user to exercise conscious control over their brain activity, myBrain Technologies is embarking on a medical strategy with the development of an alternative offer to drug treatments to improve anxiety and depressive disorders.

“The health crisis related to VIDOC-19 and the resulting upheavals highlight new therapeutic needs to manage mental health disorders. The company’s new organization and the arrival of recognized experts in their field reflect myBrain Technologies’ ambition: to strengthen its position in neuroscience brain training solutions by accelerating the large-scale commercial deployment of melomind TM, and to guide its medical neurofeedback solution towards clinical development,” said Yohan Attal, President and Co-Founder of myBrain Technologies.

To carry out its projects, myBrain Technologies has appointed Philippe Hartmanshenn, Chief Operating Officer (CO

O) Philippe Hartmanshenn has spent more than 15 years as President, Chief Executive Officer and Chief Operating Officer of several Toshiba Group subsidiaries in France, where he led the launch and development of new activities. By leading the management of transversal projects integrating strategic, commercial, industrial and financial components, he has developed a multidisciplinary expertise that will be essential for the success of the next steps in the company’s growth. Alongside Yohan Attal, Chairman of myBrain Technologies, he will oversee financial activities, HR, partnerships and development projects.

“myBrain Technologies is an exciting young company! For what it has already accomplished in the field of research and development of innovative neurofeedback solutions, but also for the tremendous challenge it now faces to industrialize its offer and successfully enter a volume market in France and internationally. I am very happy to join the team to take part in this success story in the making”. states Philippe Hartmanshenn.

myBrain Technologies relies on a strengthened sales department for the deployment in France and internationally of the digital marketing strategy of melomindTM, and on the expertise of Dr Caroline Atlani, Medical Director (CMO) consultant. She will oversee clinical studies, medical affairs, professional relations and scientific communication, with a view to obtaining “medial device” status for the neurofeedback solution in development in Europe and the United States.

“I am very pleased to contribute to the myBrain Technologies team and I am proud to advise them on strategy. medical and clinical. The coherent, integrative and personalised neurophysiological approach that the company is developing covers three dimensions: diagnostic assistance, behavioural psycho-body therapy and long-term patient monitoring”. states Dr. Caroline Atlani.About myBrain Technologies neurofeedback technologies

The products of myBrain Technologies are developed by neuroscientists in collaboration with the Brain Institute in Paris. They are brain training solutions that allow to control brain activity in order to increase well-being and deep relaxation, both for home use and as part of a follow-up treatment. The goal of these neurofeedback technologies is to allow the user to modulate Alpha waves, naturally generated by the brain, to minimize symptoms related to stress and anxiety. The application of these innovative solutions connected to the clinical field will allow, beyond the benefits for patients and healthcare professionals, the collection and analysis of unprecedented data via artificial intelligence tools, the identification of digital biomarkers, which will advance fundamental and clinical scientific research to better treat diseases with a neurological component.

About myBrain Technologies – 

myBrain Technologies is a French company, created by neuroscientists, which develops neuro-technological brain training solutions, in partnership with the Brain Institute. myBrain Technologies has complete control of the entire chain of its solutions, which includes research, design and development of the hardware and software suite, all of which is protected by strong intellectual and industrial property.

L’article myBrain Technologies presents its new ambitions with a strengthened management team est apparu en premier sur Melomind.

December 4-7, 2019 – myBrain Technologies at the French Psychiatry Congress 2019 in Nice, France

All information about the event here.

L’article French Congress of Psychiatry – myBrain Technologies presents its latest advances in the field of mental health est apparu en premier sur Melomind.

December 4, 2019 — myBrain Technologies, a company specializing in neuro-technological solutions to improve the quality of life and well-being of people, announces the positive results of the first part of its Neurorelax study, conducted in collaboration with the ICM – Institut du Cerveau et de la Moelle Epinière in Paris.

The clinical study Neurorelax, longitudinal, randomized, double-blinded is composed of a group that performs thetraining with real neurofeedback (NF) melomind, and a second group called “mock neurofeedback” or placebo that performs training based on realistic false neurofeeback. The study was carried out on 34 subjects in two contexts experimental: the first “Supervised” in the laboratory, the second “Semi-supervised” in the company.

L’article Institut du Cerveau et de la Moëlle Épinière – myBrain Technologies presents positive results of Neurorelax study est apparu en premier sur Melomind.

December 2, 2019 – Publication of the article “myBrain: in the clinic bath, headfirst” in BioTechFinances.

L’article BioTechFinances – myBrain Technologies showcases its approach to the mental health market est apparu en premier sur Melomind.

November 16, 2019 – Presentation of neurofeedback with melomind™️, in the France 2 TV news.

In this segment entitled “Brain: Learning how to tame your neurons”, discover how neurofeedbackThis protocol has been used since the 1960s to treat cognitive disorders such as ADHD, depression, anxiety, etc. … Helps to improve everyone’s daily life and mental health.

L’article JT France 2 – Neurofeedback by melomind™️ on “Brain: Learn how to tame your neurons.” est apparu en premier sur Melomind.

L’article Europe 1 – Interview with Yohan Attal, CEO, on the occasion of Mental Health Day 2019 est apparu en premier sur Melomind.

myBrain Technologies is proud to be part of the first promotion of the Digital Pharma Lab

On December 9, 2019, the launch ceremony of the Digital Pharma Lab, an event hosted by BPi France, took place. The opportunity to launch an acceleration program for innovative start-ups in the PharmaTech sector, of which myBrain Technologies is a part.

Digital Pharma Lab, le 1er accélérateur PharmaTech en Europe

L’article Digital Pharma Lab – myBrain Technologies joins Europe’s leading Pharmatech accelerator est apparu en premier sur Melomind.

July 02, 2020

Are you anxious, stressed, insomniac, depressed? Rather than resorting to medication, try digital alternative medicine with melomind™️.

Designed by neuroscience researchers, it captures the alpha waves emitted by the brain, analyses them and sends back sound signals that are supposed to help the user work on his mind, strengthen his spirit, relax, and treat stress or anxiety (neurofeedback).

Download the article (.pdf)

L’article Healing oneself differently with digital and melomind™️ est apparu en premier sur Melomind.

June 6, 2019 – The ICM receives myBrain Technologies at its Open Brain Bar event at the EDF Foundation, around the theme “When emotions speak to us”.

How do we make the (right) decisions? What happens in our brains when we fall in love? Is everyone cut out to be an entrepreneur? Why don’t we always remember our dreams? And what’s it for? How are we influenced by advertising? What is burn-out and how can it be avoided?

These are all exciting questions that were discussed on June 6th by our Research team.

All the details of the event can be found here.

L’article Institut du Cerveau et de la Moëlle Épinière – The myBrain Technologies Research Team invited to the Open Brain Bar est apparu en premier sur Melomind.